Devonian Health Group Inc. DVHGF
4.80 USD -1.08 (-18.30%)
At closeNov 3, 2026, 4:00 PM EST
4.80 Day range 4.80
4.27 52-week range 10.65
- YTD
- +12.41%
- 1 year
- +12.41%
- Market cap
- 13.35M
- EPS (ttm)
- -1.89
- YTD return
- +12.41%
- 1-year return
- +12.41%
- Volume
- 400
- Avg volume
- 71
- Open
- 4.80
- Previous close
- 5.88
- Day's range
- 4.80 – 4.80
- 52-week range
- 4.27 – 10.65
6M -5.85 (-54.93%)
News
Devonian Health Group Receives Health Canada Authorization to Evaluate Novel Thykamine™ Formulation for Prevention of Radiation-Induced Skin Injury in Breast Cancer Patients 
Devonian Health Group Provides Update on its Planned NYSE American Listing 
Devonian Health Group Provides Update on its Planned NYSE American Listing 
Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American 
Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay 
Devonian Health Group Anticipates to Commence Trading on the NYSE American 
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering 
Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering 
Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years 
Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026
Your note
Sign in to keep a note on DVHGF — it syncs with the Stock Master app.